A Phase II Multi-Arm (Basket) Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination With Pembrolizumab, as First-Line Treatment for Patients With Metastatic NSCLC, SCCHN, or Metastatic mUBC
Latest Information Update: 21 Aug 2024
At a glance
- Drugs IO102 IO103 (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Bladder cancer; Head and neck cancer; Non-small cell lung cancer; Oropharyngeal cancer; Pelvic cancer; Renal cancer; Squamous cell cancer; Ureteral neoplasms; Urethral cancer; Urogenital cancer
- Focus Therapeutic Use
- Acronyms KEYNOTE-D38
- Sponsors IO Biotech
- 13 Aug 2024 According to an IO Biotech media release, the Company plans to share updates from the NSCLC cohort, which also completed enrollment, at a medical meeting this fall.
- 25 Jul 2024 According to an IO Biotech media release, data for the complete squamous cell carcinoma of the head and neck (SCCHN) cohort from this study has been accepted for poster presentation at the European Society for Medical Oncology (ESMO) Congress 2024 and will be presented at the Congress, which takes place in Barcelona from September 13-17, 2024.
- 23 Jul 2024 Status changed from recruiting to active, no longer recruiting.